Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

fludarabine phosphate 9Cyclophosphamide 9Whole-Body Irradiation 8Mycophenolic Acid 8Cyclosporine 8Cord Blood Stem Cell Transplantation 7fludarabine 5Peripheral Blood Stem Cell Transplantation 4Busulfan 4Arsenic Trioxide 4Antilymphocyte Serum 4Transplantation 3Thiotepa 3Tacrolimus 3Radiotherapy 3Etoposide 3Cytarabine 3Methylprednisolone 2Methotrexate 2Melphalan 2Carmustine 2Azacitidine 2thymoglobulin 1lonafarnib 1lintuzumab 1itacitinib 1Vorinostat 1Tretinoin 1Tetradecanoylphorbol Acetate 1Teriparatide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia, Refractory, with Excess of Blasts × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡